Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry Disease Following a Successful ...
Clear Path for Biologics License Application (BLA) Submission One Short-Term Safety and Efficacy Study Required to Support Full Approval In Parallel, Protalix to Conduct Phase III Head-to-Head Superiority Trial Comparing PRX-102 Versus Fabrazyme® CARMIEL, …